263 View: Overview Glossary  HistCite Guide
Author(s)ODA T; KANAI Y; OYAMA T; YOSHIURA K; SHIMOYAMA Y; BIRCHMEIER W; SUGIMURA T; HIROHASHI S
TitleE-CADHERIN GENE-MUTATIONS IN HUMAN GASTRIC-CARCINOMA CELL-LINES
SourcePROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 91 (5): 1858-1862
Date1994 MAR 1
TypeJournal : Article
LCR1   NCR: 48   LCS: 0   GCS: 210
Comment 
AddressNATL CANC CTR,RES INST,DIV PATHOL,CHUO KU,TOKYO 104,JAPAN.
UNIV TSUKUBA,INST CLIN MED SURG,TSUKUBA,IBARAKI 305,JAPAN.
MAX DELBRUCK CTR MOLEC MED,D-13122 BERLIN,GERMANY.
AbstractReduced expression of E-cadherin has been regarded as one of the main molecular events involved in dysfunction of the cell-cell adhesion system, triggering cancer invasion and metastasis. However, even with a sufficient amount of E-cadherin, cell-cell adhesion is sometimes lost in ''diffusely invasive'' human carcinomas. Ten human cancer cell lines, showing growth characterized morphologically by loose cell-cell adhesion, were analyzed for possible structural abnormalities of their expressed E-cadherin. Four of the cell lines showed strong mRNA and protein expression with no nucleotide sequence abnormalities, and mRNA was absent in four other cell lines. mRNA sequence was abnormal in the remaining two gastric carcinoma cell lines. In MKN45 (poorly differentiated adenocarcinoma), this involved a 12-bp in-frame deletion with strong expression of mRNA and protein. In KATO-III (signet ring cell carcinoma), there were four mRNA species with insertions of different sizes, among which the major transcripts (with a 7-bp insertion) caused a frameshift, and expression of both mRNA and protein was markedly reduced. In these two cell lines, DNA mutations were detected around exon-intron junctions, revealing that aberrant RNA splicing was the cause of the mRNA abnormalities. In addition, the wild-type allele of the E-cadherin locus was lost, suggesting that the E cadherin gene had been inactivated by two hits (mutation and allele loss), similar to the mechanism for inactivation of tumor suppressor genes.
CR BEHRENS J, 1985, J CELL BIOL, V101, P1307
BEHRENS J, 1989, J CELL BIOL, V108, P2435
BEHRENS J, 1992, SEMIN CELL BIOL, V3, P169
BELASCO JG, 1988, GENE, V72, P15
BUBENIK J, 1973, INT J CANCER, V11, P765
BUSSEMAKERS MJG, 1992, CANCER RES, V52, P2916
CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751
CHEN WC, 1991, J CELL BIOL, V114, P319
DAAR IO, 1988, MOL CELL BIOL, V8, P802
DEXTER DL, 1979, CANCER RES, V39, P1020
DORUDI S, 1993, AM J PATHOL, V142, P981
FRIXEN UH, 1991, J CELL BIOL, V113, P173
GAMALLO C, 1993, AM J PATHOL, V142, P987
GUMBINER B, 1986, J CELL BIOL, V102, P457
HIRANO S, 1992, CELL, V70, P293
KEMLER R, 1989, CURR OPIN CELL BIOL, V1, P892
KINJO M, 1979, BRIT J CANCER, V39, P15
LEIBOVITZ A, 1976, CANCER RES, V36, P4562
LEVINE AJ, 1990, BIOESSAYS, V12, P60
LIM SK, 1992, MOL CELL BIOL, V12, P1149
MAQUAT LE, 1981, CELL, V27, P543
MAYER B, 1993, CANCER RES, V53, P1690
MOTOYAMA T, 1983, JPN J CANCER RES, V74, P679
NOSE A, 1990, CELL, V61, P147
ODA T, 1992, CANCER RES, V52, P3674
ODA T, 1993, BIOCHEM BIOPH RES CO, V193, P897
OKA H, 1993, CANCER RES, V53, P1696
OZAWA M, 1990, CELL, V63, P1033
PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119
QUINN J, 1993, J BIOL CHEM, V268, P7832
RASBRIDGE SA, 1993, J PATHOL, V169, P245
RINGWALD M, 1991, NUCLEIC ACIDS RES, V19, P6533
SAMBROOK J, 1989, MOL CLONING LABORATO
SATO T, 1990, CANCER RES, V50, P7184
SCHIPPER JH, 1991, CANCER RES, V51, P6328
SEMPLE TU, 1978, CANCER RES, V38, P1345
SHIMOYAMA Y, 1989, J CELL BIOL, V109, P1787
SHIMOYAMA Y, 1991, CANCER LETT, V57, P131
SHIMOYAMA Y, 1991, CANCER RES, V51, P2185
SHIMOYAMA Y, 1992, CANCER RES, V52, P5770
SHIOZAKI H, 1991, AM J PATHOL, V139, P17
SOMMERS CL, 1991, CELL GROWTH DIFFER, V2, P365
SUZUKI Y, 1991, ANAL BIOCHEM, V192, P82
TAKEICHI M, 1991, SCIENCE, V251, P1451
TSUDA H, 1990, P NATL ACAD SCI USA, V87, P6791
UMBAS R, 1992, CANCER RES, V52, P5104
VLEMINCKX K, 1991, CELL, V66, P107
YAMADA T, 1985, JPN J CANCER RES, V76, P967